These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 19065525)

  • 1. [Advance of the study on LRRK2 gene in Parkinson's disease].
    Zhang Y; Chen S
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Dec; 25(6):657-9. PubMed ID: 19065525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LRRK2 in Parkinson's disease: protein domains and functional insights.
    Mata IF; Wedemeyer WJ; Farrer MJ; Taylor JP; Gallo KA
    Trends Neurosci; 2006 May; 29(5):286-93. PubMed ID: 16616379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of LRRK2 kinase activity in the pathogenesis of Parkinson's disease.
    Greggio E
    Biochem Soc Trans; 2012 Oct; 40(5):1058-62. PubMed ID: 22988865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical molecular genetics for PARK8 (LRRK2)].
    Tomiyama H; Hatano T; Hattori N
    Brain Nerve; 2007 Aug; 59(8):839-50. PubMed ID: 17713120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemical and molecular features of LRRK2 and its pathophysiological roles in Parkinson's disease.
    Seol W
    BMB Rep; 2010 Apr; 43(4):233-44. PubMed ID: 20423607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measurement of LRRK2 and Ser910/935 phosphorylated LRRK2 in peripheral blood mononuclear cells from idiopathic Parkinson's disease patients.
    Dzamko N; Chua G; Ranola M; Rowe DB; Halliday GM
    J Parkinsons Dis; 2013; 3(2):145-52. PubMed ID: 23938344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson's disease.
    Gandhi PN; Chen SG; Wilson-Delfosse AL
    J Neurosci Res; 2009 May; 87(6):1283-95. PubMed ID: 19025767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathogenic LRRK2 mutations, through increased kinase activity, produce enlarged lysosomes with reduced degradative capacity and increase ATP13A2 expression.
    Henry AG; Aghamohammadzadeh S; Samaroo H; Chen Y; Mou K; Needle E; Hirst WD
    Hum Mol Genet; 2015 Nov; 24(21):6013-28. PubMed ID: 26251043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation.
    Luzón-Toro B; Rubio de la Torre E; Delgado A; Pérez-Tur J; Hilfiker S
    Hum Mol Genet; 2007 Sep; 16(17):2031-9. PubMed ID: 17584768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leucine-rich repeat kinase 2 (LRRK2) cellular biology: a review of recent advances in identifying physiological substrates and cellular functions.
    Drolet RE; Sanders JM; Kern JT
    J Neurogenet; 2011 Dec; 25(4):140-51. PubMed ID: 22077787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leucine-rich repeat kinase 2 inhibitors: a review of recent patents (2011 - 2013).
    Kethiri RR; Bakthavatchalam R
    Expert Opin Ther Pat; 2014 Jul; 24(7):745-57. PubMed ID: 24918198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphorylation of LRRK2: from kinase to substrate.
    Lobbestael E; Baekelandt V; Taymans JM
    Biochem Soc Trans; 2012 Oct; 40(5):1102-10. PubMed ID: 22988873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dominant-negative effects of LRRK2 heterodimers: a possible mechanism of neurodegeneration in Parkinson's disease caused by LRRK2 I2020T mutation.
    Ohta E; Kawakami F; Kubo M; Obata F
    Biochem Biophys Res Commun; 2013 Jan; 430(2):560-6. PubMed ID: 23220480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular biology changes associated with LRRK2 mutations in Parkinson's disease.
    Lu YW; Tan EK
    J Neurosci Res; 2008 Jul; 86(9):1895-901. PubMed ID: 18338801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MAPK-pathway activity, Lrrk2 G2019S, and Parkinson's disease.
    White LR; Toft M; Kvam SN; Farrer MJ; Aasly JO
    J Neurosci Res; 2007 May; 85(6):1288-94. PubMed ID: 17385669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A trojan horse for Parkinson's disease.
    Hu Y; Tong Y
    Sci Signal; 2010 Apr; 3(116):pe13. PubMed ID: 20371768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations in LRRK2 as a cause of Parkinson's disease.
    Giasson BI; Van Deerlin VM
    Neurosignals; 2008; 16(1):99-105. PubMed ID: 18097165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential effects of familial parkinson mutations in LRRK2 revealed by a systematic analysis of autophosphorylation.
    Kamikawaji S; Ito G; Sano T; Iwatsubo T
    Biochemistry; 2013 Sep; 52(35):6052-62. PubMed ID: 23924436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and pathologic features of families with LRRK2-associated Parkinson's disease.
    Whaley NR; Uitti RJ; Dickson DW; Farrer MJ; Wszolek ZK
    J Neural Transm Suppl; 2006; (70):221-9. PubMed ID: 17017533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2.
    Deng X; Dzamko N; Prescott A; Davies P; Liu Q; Yang Q; Lee JD; Patricelli MP; Nomanbhoy TK; Alessi DR; Gray NS
    Nat Chem Biol; 2011 Apr; 7(4):203-5. PubMed ID: 21378983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.